ライフサイエンスコーパス: intrauterine

1 nferred by (+)-naloxone administration after intrauterine administration of heat-killed E. coli.

2 Intrauterine administration of LPS on day 17 of gestatio

3 Intrauterine administration of LPS, both under ultrasoun

4 inflammation-induced preterm delivery model, intrauterine administration of SP-A significantly inhibi

5 ze evidence that allergy is a consequence of intrauterine and early life immune dysregulation, with s

6 Nutritional status during intrauterine and early postnatal life impacts the risk o

7 We hypothesise that both intrauterine and genetic factors influence the co-occurr

8 observations support previous findings that intrauterine and perinatal factors can have long-lasting

9 ternal smoking and the relative roles of the intrauterine and postnatal environment is also warranted

10 In humans, mutations in IGF1 or IGF1R cause intrauterine and postnatal growth restriction; however,

11 ts complex pathogenesis likely involves poor intrauterine and postnatal nutrition, exposure to microb

12 Intrauterine and systemic infection and inflammation cau

13 pongy myocardium." The disorder results from intrauterine arrest of compaction of the loose interwove

14 Arrhythmia symptoms and intrauterine beta-blocker exposure each predicted -7 bea

15 tion that replicates the in utero fetus, but intrauterine body composition reference charts for prete

16 the colonized vagina to the normally sterile intrauterine cavity is a well-documented cause of preter

17 e placenta restricts microbial access to the intrauterine compartment.

18 cal factors including age, prematurity, sex, intrauterine complications, and postnatal adversity.

19 Furthermore, modeling of intrauterine conditions has indicated a substantially gr

20 ts that neither genetic influences of CD nor intrauterine conditions have adverse effects on offsprin

21 A better understanding of intrauterine conditions that influence offspring disease

22 sparing response may be affected by adverse intrauterine conditions, this area of research has been

23 Immune tolerance caused by intrauterine contact with the parasite could explain thi

24 traceptives such as the subdermal implant or intrauterine contraception; most counseling focused on o

25 implants, whereas 16% had never heard of an intrauterine contraceptive device (IUD).

26 nital malformations, but also in unexplained intrauterine death and sudden unexpected death in infanc

27 The risk of intrauterine death did not differ between patients and c

28 In the vesicoamniotic shunt group one intrauterine death occurred and three pregnancies were t

29 Intrauterine death was observed in 1 fetus (<1%) in the

30 o group: abortion, n=22; blighted ovum, n=1; intrauterine death, n=2; early neonatal death, n=1; and

31 oup: abortion, n=20; blighted ovum, and n=2; intrauterine death, n=2; placebo group: abortion, n=22;

32 fetal outcomes, including preterm labor and intrauterine death.

33 ), can result in intracranial hemorrhage and intrauterine death.

34 men had a miscarriage, and three fetuses had intrauterine death.

35 CHDs with univentricular outcome (P<0.0001), intrauterine deaths (P=0.01), and terminations of pregna

36 re 19 (17%) spontaneous abortions and 2 (2%) intrauterine deaths.

37 stores in the KO fetus, suggesting that this intrauterine deficiency might have deleterious consequen

38 CHDs with univentricular outcome (P<0.0001), intrauterine demise (P=0.036), and early termination (P<

39 ble to a high vulnerability to stress during intrauterine development of a maturing organism.

40 Mammalian viviparity (intrauterine development of the fetus) introduced a new

41 (DMPA; n = 32), the levonorgestrel-releasing intrauterine device (LNG-IUD; n = 27), oral contraceptiv

42 The intrauterine device is not a risk factor for this condit

43 s and women enrolled in CHOICE, 72% chose an intrauterine device or implant (LARC methods); the remai

44 distinguish those reporting use of (1) LARC (intrauterine device or implant), (2) oral contraceptives

45 ould select birth control pills; condoms; an intrauterine device or implant; injection, patch, or rin

46 t brachial plexus injury, dislodgement of an intrauterine device, and vaginal granulation tissue.

47 ing reversible contraceptive methods include intrauterine devices (IUDs) and subdermal implants and s

48 Contraceptive implants and intrauterine devices (IUDs) are long-acting reversible c

49 ng on providing counselling and insertion of intrauterine devices (IUDs) or progestin implants and 20

50 eversible contraception (LARC), specifically intrauterine devices and implants, offers an unprecedent

51 sing other contraceptive methods, except for intrauterine devices and permanent methods, had 3.1-4.1

52 g all other contraceptive methods except for intrauterine devices and permanent methods.

53 e little evidence to support a strong causal intrauterine effect of incrementally greater maternal BM

54 However, we found evidence for acausal intrauterine effect of maternal BMI on newborn methylati

55 h maternal diabetes, suggesting sex-specific intrauterine effects on adult metabolic health.

56 owever, it is unclear whether this is due to intrauterine effects.

57 ies of human subjects exposed to an abnormal intrauterine environment (e.g., individuals with a low b

58 transgenic animals lacking NOS3 that adverse intrauterine environment alters fetal programming of vas

59 c animals, we previously showed that adverse intrauterine environment alters vascular reactivity in a

60 The intrauterine environment and fetal genes contribute to t

61 ion, fibrosis, and edema result in a hypoxic intrauterine environment and release of cytokines that s

62 lacenta that contributes to variation in the intrauterine environment and thus presents the opportuni

63 carried out in placenta, the effector of the intrauterine environment as conveyed by the maternal exp

64 Our study indicates that adverse intrauterine environment contributes, along with multipl

65 The intrauterine environment during pregnancy is a critical

66 rozygous NOS3(+/-) (KOM: mother with adverse intrauterine environment from NOS3 deficiency), paternal

67 s associated with pregnancy and the maternal intrauterine environment in ASDs.

68 The intrauterine environment is a major contributor to incre

69 The intrauterine environment is particularly vulnerable to e

70 The intrauterine environment of the fetus is a preeminent ac

71 may be attributable to causal effects of the intrauterine environment or genetic and postnatal enviro

72 d dopamine-containing socket cells sense the intrauterine environment through cellular endings expose

73 gs suggest that adaptation to the suboptimal intrauterine environment underlying chronic causes of pr

74 that supports prenatal growth in the hypoxic intrauterine environment, to the postnatal state wherein

75 epigenetic mechanisms and the effect of the intrauterine environment.

76 fluenced by parental characteristics and the intrauterine environment.

77 Our observation appears to be explained by intrauterine environmental differences or by differences

78 These results support the notion that intrauterine exposure to a major psychological maternal

79 Our results support the idea that intrauterine exposure to GDM has long-lasting effects on

80 Intrauterine exposure to gestational diabetes mellitus (

81 ion (MR) to investigate the causal effect of intrauterine exposure to greater maternal body mass inde

82 This finding suggests that intrauterine exposure to insufficient thyroid hormone le

83 nd obesity in early life in association with intrauterine exposure to maternal hyperglycemia, a commo

84 and diagnosed CD (n = 3,202) to determine if intrauterine exposures associated with CD could affect o

85 fatty liver disease (NAFLD) may lie in early intrauterine exposures.

86 her causes included hereditary factors (4%), intrauterine factors (2.0%) and perinatal factors (4.4%)

87 male mice developed anti-KEL alloantibodies; intrauterine fetal anemia and/or demise occurred in a su

88 eous abortion (aRR = 5.9; 95% CI, 1.8-19.7), intrauterine fetal death (aRR = 9.0; 95% CI, 1.2-65.5),

89 sions (one pregnancy resulted in p-aHUS, one intrauterine fetal death occurred, and seven pregancies

90 Intrauterine fetal death or stillbirth occurs in approxi

91 y, major fetal neurologic abnormalities, and intrauterine fetal death).

92 molecular genetic evaluation of 91 cases of intrauterine fetal death, missense mutations associated

93 There were 3 intrauterine fetal deaths (1 woman had used LMWH); 9 cas

94 milar control patients, were discovered in 3 intrauterine fetal deaths (3.3% [95% CI, 0.68%-9.3%]).

95 In addition, 5 intrauterine fetal deaths hosted SCN5A rare nonsynonymou

96 Of the 872 terminations of pregnancy and intrauterine fetal deaths, 189 fetopsies were available:

97 Intrauterine fetal demise and/or preterm birth were obse

98 births were normal with the exceptions of an intrauterine fetal demise owing to acrania and a molar p

99 Intrauterine fetal growth restriction (IUGR) is often as

100 rization of syncytiotrophoblasts, leading to intrauterine fetal growth restriction, fetal liver hypoc

101 Early diagnosis offers an opportunity for a intrauterine fetal intervention in potentially lethal ca

102 natal ultrasound scan showed a single, live, intrauterine foetus corresponding to a gestational age o

103 nd whose mothers have chorioamnionitis or an intrauterine foreign body.

104 genase were significantly more vulnerable to intrauterine GAS infection than were wild-type mice and

105 natal ultrasound scan showed a single, live, intrauterine gestation corresponding to a gestational ag

106 impaired DLK1 expression and to predict poor intrauterine growth and complications of pregnancy.

107 rnal level of education, and less than -1 SD intrauterine growth are associated with eating difficult

108 Plasmodium falciparum exposure had retarded intrauterine growth between gestational ages of 212 and

109 It is unclear whether abnormal intrauterine growth influences arterial morphology durin

110 ny stimulus or aggression experienced during intrauterine growth into physiologic and metabolic alter

111 These results indicate that the intrauterine growth of fetal arterial LD and wall layer

112 The influence of genetic factors and intrauterine growth on comorbidity between these disorde

113 examined the extent to which information on intrauterine growth patterns improved prediction of chil

114 ry tract (8/36 [22%] vs 2/71 [3%]; p=0.002), intrauterine growth restriction (34/37 [92%] vs 34/70 [4

115 Intrauterine growth restriction (IUGR) affects up to 10%

116 Prenatal and postnatal factors such as intrauterine growth restriction (IUGR) and high-fat (HF)

117 OINTS: Maternal nutrient restriction induces intrauterine growth restriction (IUGR) and leads to heig

118 Intrauterine growth restriction (IUGR) confers heritable

119 Intrauterine growth restriction (IUGR) decreases serum I

120 complications such as preeclampsia (PE) and intrauterine growth restriction (IUGR) in 20% of patient

121 KEY POINTS: Intrauterine growth restriction (IUGR) increases offspri

122 Intrauterine growth restriction (IUGR) increases the ris

123 Intrauterine growth restriction (IUGR) is a common compl

124 Intrauterine growth restriction (IUGR) is a pathology of

125 Intrauterine growth restriction (IUGR) leads to developm

126 Placental insufficiency and intrauterine growth restriction (IUGR) of the fetus affe

127 We hypothesized that intrauterine growth restriction (IUGR) offspring hearts

128 ry measure, we also evaluated the effects of intrauterine growth restriction (IUGR) on carotenoid sta

129 Our objective was to determine the impact of intrauterine growth restriction (IUGR) on pancreatic vas

130 duced skeletal muscle mass in the fetus with intrauterine growth restriction (IUGR) persists into adu

131 Intrauterine growth restriction (IUGR) reduces skeletal

132 KEY POINTS: Rodent models of intrauterine growth restriction (IUGR) successfully iden

133 Rodent models of intrauterine growth restriction (IUGR) successfully iden

134 KEY POINTS: Adults who were affected by intrauterine growth restriction (IUGR) suffer from reduc

135 med MIRAGE syndrome that is characterized by intrauterine growth restriction (IUGR) with gonadal, adr

136 ce also leads to decreased beta cell growth, intrauterine growth restriction (IUGR), and impaired pla

137 TRACT: Maternal nutrient restriction induces intrauterine growth restriction (IUGR), increasing later

138 BSTRACT: Maternal nutrient reduction induces intrauterine growth restriction (IUGR), increasing risks

139 Metabolic syndrome (MetS), following intrauterine growth restriction (IUGR), is epigeneticall

140 as not been shown to prevent preeclampsia or intrauterine growth restriction (IUGR).

141 ectd1 results in mid-gestation lethality and intrauterine growth restriction (IUGR).

142 Congenital infection is also associated with intrauterine growth restriction (IUGR).

143 , 0.76 [95% CI, 0.62 to 0.95]), 1% to 5% for intrauterine growth restriction (RR, 0.80 [CI, 0.65 to 0

144 High-altitude hypoxia causes intrauterine growth restriction and cardiovascular progr

145 often leads to abortion, premature delivery, intrauterine growth restriction and low birth weight.

146 ads to devastating fetal outcomes, including intrauterine growth restriction and microcephaly.

147 ctor to poor placental perfusion, leading to intrauterine growth restriction and preeclampsia, is the

148 rther distinguish placental dysfunction from intrauterine growth restriction and reveal a role for th

149 ic membranes of placentas from newborns with intrauterine growth restriction and underlying congenita

150 may also have a role in the investigation of intrauterine growth restriction and unexplained stillbir

151 Both models lead to intrauterine growth restriction but dissociate between a

152 ging mosquito-borne virus recently linked to intrauterine growth restriction including abnormal fetal

153 We find a sexually dimorphic response; intrauterine growth restriction is associated with subst

154 dies have evaluated the effect of malaria on intrauterine growth restriction on the basis of the feta

155 asion shortly after implantation, along with intrauterine growth restriction or embryonic death.

156 with various confounding factors, including intrauterine growth restriction or factors related to th

157 ome (3 women had used LMWH); and 11 cases of intrauterine growth restriction or placental insufficien

158 with normal outcomes (N = 29) and those with intrauterine growth restriction or preeclampsia (N = 12)

159 amino acid transport are decreased in human intrauterine growth restriction our data are consistent

160 priate management of pregnancies at risk for intrauterine growth restriction relies on accurate ident

161 e of the p.[P33S(;)P168S] variant in ROP and intrauterine growth restriction suggests that it also ma

162 ommon pregnancy complication associated with intrauterine growth restriction that may influence respi

163 a, congenital transmission, pup viral loads, intrauterine growth restriction, and pup mortality compa

164 c mutation of the mouse Mtrr gene results in intrauterine growth restriction, developmental delay, an

165 ognitive impairment, behavioral alterations, intrauterine growth restriction, feeding problems, and v

166 trate that ZIKV(BR) infects fetuses, causing intrauterine growth restriction, including signs of micr

167 condition is characterized by short stature, intrauterine growth restriction, lipoatrophy and a facia

168 l outcomes for the fetus and newborn include intrauterine growth restriction, low birth weight, and s

169 DNA in amniotic fluid and/or newborn saliva, intrauterine growth restriction, preterm deliveries, and

170 ment, and pregnancy complications, including intrauterine growth restriction, preterm delivery, and s

171 a single First Nations population and causes intrauterine growth restriction, severe microcephaly, cr

172 us (ZIKV) infection in pregnant women causes intrauterine growth restriction, spontaneous abortion, a

173 nancy complications, including preeclampsia, intrauterine growth restriction, spontaneous abortion, p

174 rlying placental pathologies associated with intrauterine growth restriction, which is a significant

175 xy for the pathological process of interest, intrauterine growth restriction.

176 or gestational age and those with pathologic intrauterine growth restriction.

177 actor and placental growth factor levels and intrauterine growth restriction.

178 rent spontaneous abortion, preeclampsia, and intrauterine growth restriction.

179 gical deficits, hearing and vision loss, and intrauterine growth restriction.

180 ntal," which was preceded by preeclampsia or intrauterine growth restriction.

181 d nutritional status who were at low risk of intrauterine growth restriction.

182 e nutritional status who were at low risk of intrauterine growth restriction.

183 with structural malformations and linked to intrauterine growth restriction.

184 y represent a useful therapeutic approach to intrauterine growth retardation due to placental vascula

185 and congenital anemia accompanied by either intrauterine growth retardation or neutropenia.

186 ients from 4 kindreds, all of whom displayed intrauterine growth retardation, chronic neutropenia, an

187 was characterized by ID, ASD, microcephaly, intrauterine growth retardation, febrile seizures in inf

188 ernal interface results in pre-eclampsia and intrauterine growth retardation.

189 cerebellar hypoplasia, immunodeficiency, and intrauterine growth retardation.

190 irth weight and gestational age at delivery, intrauterine growth, and maternal and infant iron status

191 a risk factor for retinopathy and restricted intrauterine growth.

192 relation between fetal fatty acid supply and intrauterine growth.

193 ramming of offspring phenotype by suboptimal intrauterine growth.

194 ontribute to the clinical outcomes following intrauterine HCMV infection.

195 tal intermediary responsible for maintaining intrauterine homeostasis.

196 le of O-T1D suggests that factors other than intrauterine hyperglycemia may contribute to the decreas

197 Intrauterine hypoxia is a reason for impaired kidney dev

198 To address this, both an in vivo mouse intrauterine (i.u.) GAS infection model and an in vitro

199 e role of B cells in preconception and early intrauterine immune priming.

200 Intrauterine infection (chorioamnionitis) aggravates neo

201 odels are used to study mechanisms that link intrauterine infection and preterm birth (PTB).

202 common cause of spontaneous preterm birth is intrauterine infection in the mother.

203 Intrauterine infection is a major detriment for maternal

204 al and decidual macrophages and used a novel intrauterine infection model of GAS in mice lacking the

205 mucus could contribute to increased rates of intrauterine infection seen in women with preterm birth.

206 In this model, asymptomatic intrauterine infection was observed following i.v. rhCMV

207 Chorioamnionitis is caused by intrauterine infection with microorganisms including Can

208 the hydrosalpinx induction in CBA/J mice by intrauterine infection with plasmid-free C. muridarum a

209 To mimic intrauterine infection, lipopolysaccharide (LPS) is comm

210 s in infants born with microcephaly and ZIKV intrauterine infection.

211 titis that is known to translocate and cause intrauterine infections.

212 ociation between prenatal PM2.5 exposure and intrauterine inflammation (IUI), an important risk facto

213 Intrauterine inflammation and maternal exposure to ambie

214 hat male but not female offspring exposed to intrauterine inflammation demonstrated impaired performa

215 Intrauterine inflammation is an etiological factor that

216 Intrauterine inflammation is recognized as a key mediato

217 /-)) mice exhibited a greater sensitivity to intrauterine inflammation, as indicated by decreased tim

218 Histologic chorioamnionitis (HCA) reflects intrauterine inflammation, can trigger a fetal inflammat

219 Here, we used the established mouse model of intrauterine inflammation-induced PTB to determine wheth

220 Towards this goal, we used a maternal intrauterine inflammation-induced rabbit model of CP to

221 mer nanoparticle (DNAC), in a mouse model of intrauterine inflammation.

222 Maternal intrauterine inflammation/infection is a major risk fact

223 Histological chorioamnionitis (HCA) is an intrauterine inflammatory condition that increases the r

224 O128:B12) were administered to CD1 mice via intrauterine injection at gestational day 16.

225 Intrauterine inoculation at embryonic day (E) 10, but no

226 The intrauterine inoculation of the CBA/J mice with plasmid-

227 gestational tissues were collected 8 h after intrauterine inoculation on day 14.5 of pregnancy with e

228 anism ascension to the oviduct following the intrauterine inoculation.

229 . muridarum directly into the endometrium by intrauterine inoculation.

230 developmental domain for ovulation induction/intrauterine insemination (aOR, 1.00; 95% CI, 0.57-1.77

231 nderwent in vitro fertilization (IVF) and/or intrauterine insemination (IUI) cycles in a prospective

232 going pregnancies after ovulation induction, intrauterine insemination, or IVF did not differ signifi

233 ongoing pregnancy after ovulation induction, intrauterine insemination, or IVF.

234 categorized into ART and ovulation induction/intrauterine insemination.

235 expectant management or the women underwent intrauterine insemination.

236 er, over the last 3 decades, improvements in intrauterine interventions and perinatal intensive care

237 labor was initiated on gestation day 14.5 by intrauterine (IU) injection of peptidoglycan (PGN) and p

238 ant mice to control or HFD during pregnancy (intrauterine [IU]) and lactation (L).

239 ) cell self-renewal, yet its knockout causes intrauterine lethality due to defects in trophoblast dev

240 ergenerational transmission may begin during intrauterine life via the effect of maternal CT exposure

241 smission that may operate as early as during intrauterine life.

242 Ultrasound-guided intrauterine LPS injection is a useful novel model of PT

243 hesized that less-invasive ultrasound-guided intrauterine LPS injection or intravaginal LPS administr

244 Ultrasound-guided intrauterine LPS injection reliably induces PTB in the m

245 y genetic or lifestyle factors than a causal intrauterine mechanism.

246 mic cardio-metabolic profile are causal, via intrauterine mechanisms, or due to shared familial facto

247 so, whether this association is causal, via intrauterine mechanisms, or explained by shared familial

248 amilial lifestyle confounding rather than to intrauterine mechanisms.

249 tions, providing further evidence for causal intrauterine mechanisms.

250 fects lifelong risk of offspring fatness via intrauterine mechanisms.

251 The intrauterine microclimate is critical for maternal and f

252 However, the intrauterine microenvironment is not only determined by

253 studies; information on important sequelae, intrauterine mortality, and termination of pregnancy; an

254 a (CSD) refers to an intractable diarrhea of intrauterine onset with high fecal sodium loss.

255 ining this mTOR pathway suggests that local (intrauterine or peritoneal) rapamycin administration mig

256 e women information on highly effective (ie, intrauterine or subdermal) contraceptives, the iPLEDGE p

257 umans, parturition is currently viewed as an intrauterine outbreak of inflammation, accompanied by a

258 ndings emphasize the relevance of sufficient intrauterine oxygenation for normal renal stroma differe

259 matic study of the potential implications of intrauterine perfluorocarbon exposure during critical pe

260 The intrauterine period is a critical time wherein developme

261 this effect may originate during the child's intrauterine period of life, which may have downstream n

262 hat this effect may start during the child's intrauterine period of life.

263 Serial fetal blood sampling (FBS) and intrauterine platelet transfusions (IUPT), as well as we

264 s have been shown to depend, in part, on the intrauterine position during development of female fetus

265 ed, including its uses for distinguishing an intrauterine pregnancy from a failed or ectopic pregnanc

266 ence of an adnexal mass in the absence of an intrauterine pregnancy on transvaginal sonography (LR+ 1

267 An anatomy sensitivity factor converts intrauterine pressure to regional tension through the La

268 gional contraction, which slightly increases intrauterine pressure.

269 These results suggest a possible intrauterine programming effect of maternal psychologica

270 e mass in wild-type offspring, suggesting an intrauterine programming effect.

271 evelopmental memory in islets that registers intrauterine protein restriction.

272 disease" hypothesis, which suggests that the intrauterine signals that compromise fetal growth also a

273 and (3) understanding of mechanisms by which intrauterine smoke exposure may lead to persistent, toba

274 Intrauterine surveillance and a postnatal comprehensive

275 al, we compared the levonorgestrel-releasing intrauterine system (levonorgestrel-IUS) with usual medi

276 The levonorgestrel-releasing intrauterine system (LNG-IUD), gonadotropin-releasing ho

277 urrently or recently used the progestin-only intrauterine system also had a higher risk of breast can

278 The levonorgestrel-releasing intrauterine system is considered a first-line treatment

279 I, 1.55-1.69); and users of a levonorgestrel intrauterine system, 1.4 (95% CI, 1.31-1.42).

280 long-term anticoagulation, a levonorgestrel intrauterine system, tranexamic acid (during menstrual f

281 These products include implants, intrauterine systems, and vaginal rings.

282 tic loading), (2) one environmental agent is intrauterine testosterone and (3) the mother is the majo

283 is that autism is caused by exposure to high intrauterine testosterone levels is considered in the co

284 able cases, we find evidence to suggest that intrauterine therapy provides benefits during the perina

285 associated with a leukocyte influx into the intrauterine tissues; however, the exact role these leuk

286 tral role in separating the vaginal from the intrauterine tract, the barrier properties of cervical m

287 Information on the intrauterine trajectory through which birth weight was a

288 However, the mechanism of intrauterine transmission and the cell types involved re

289 Our results suggest a mechanism for intrauterine transmission in which ZIKV gains access to

290 infection significantly reduced the rate of intrauterine transmission, from 40% to 16%.

291 of odorant binding protein six in the gut of intrauterine tsetse larvae.

292 Brain damage was confirmed through intrauterine ultrasonography and was complemented by mag

293 uch as repeated spontaneous abortion, sudden intrauterine unexpected foetal death syndrome and stillb

294 aracterized by sequential colonisation of i) intrauterine/vaginal birth associated taxa, ii) skin der

295 here is sufficient evidence to conclude that intrauterine Zika virus infection is a cause of microcep

296 nfants with presumed or laboratory-confirmed intrauterine Zika virus infection.

297 s with microcephaly associated with presumed intrauterine ZIKV infection in Salvador, Bahia, Brazil.

298 d for a variety of anomalies associated with intrauterine ZIKV infection.

299 -be-described outcomes to be associated with intrauterine ZIKV infection.

300 ng on brain tissue from a 20-week fetus with intrauterine ZIKV infection.